Keymed Biosciences (HKSE:02162) Change In Receivables : HK$-29.6 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Change In Receivables?

Keymed Biosciences's change in receivables for the quarter that ended in Dec. 2023 was HK$-20.6 Mil. It means Keymed Biosciences's Accounts Receivable increased by HK$20.6 Mil from Jun. 2023 to Dec. 2023 .

Keymed Biosciences's change in receivables for the fiscal year that ended in Dec. 2023 was HK$-29.6 Mil. It means Keymed Biosciences's Accounts Receivable increased by HK$29.6 Mil from Dec. 2022 to Dec. 2023 .

Keymed Biosciences's Accounts Receivable for the quarter that ended in Dec. 2023 was HK$17.6 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Keymed Biosciences's Days Sales Outstanding for the six months ended in Dec. 2023 was 108.88.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Keymed Biosciences's liquidation value for the six months ended in Dec. 2023 was HK$2,038.1 Mil.

Keymed Biosciences Change In Receivables Historical Data

The historical data trend for Keymed Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Change In Receivables Chart

Keymed Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-4.87

4.45

-29.63

Keymed Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial				-	4.67	-	-9.08	-20.55

Keymed Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-29.6 Mil.

Keymed Biosciences (HKSE:02162) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Keymed Biosciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	17.6	/	29.5	*	91
=	108.88

2. In Ben Graham's calculation of liquidation value, Keymed Biosciences's accounts receivable are only considered to be worth 75% of book value:

Keymed Biosciences's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2974.188	-	980.145	+	0.75 * 17.6	+	0.5 * 61.639
=	2,038.1

Keymed Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Keymed Biosciences (HKSE:02162) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

64Z:Germany

Address

No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219

Website

https://www.keymedbio.com

Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.

Executives

Chen Bo	2201 Interest of corporation controlled by you
Eagle Hero Management Limited	2101 Beneficial owner
Trident Trust Company (hk) Limited	2301 Trustee
Moonshot Holdings Limited	2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences (HKSE:02162) Headlines

No Headlines